clofarabine / Generic mfg. - LARVOL DELTA

Real-world AML survival paradox: Early escalation vs. sustained remission (ASH 2025) - "Patients were stratified into two cohorts: Cohort A (early escalation, n=1,460), comprising patients who received either second-line chemotherapy (including fludarabine, cladribine, gilteritinib, enasidinib, revumenib, olutasidenib, etoposide, or clofarabine) or hematopoietic stem cell transplant (HSCT) as salvage therapy within 6 months of completing initial therapy; and Cohort B (no escalation, n=10,540), consisting of patients who received no additional therapy during this same period. Our findings highlight the complex interplay between disease biology and treatment interventions: achieving MRD-negativity remains critical, but when MRD-positivity occurs, subsequent treatment decisions based on disease genetics prove critical. Prospective studies incorporating molecular MRD monitoring are needed to confirm these findings and further optimize post-remission therapy approaches."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia

Results of abatacept addition to post transplant cyclophosphamide-based GVHD prophylaxys in allogeneic hematopoyetic stem cell transplantation (ASH 2025) - "All patients received peripheral blood as graft source and all patients received GVHD prophylaxis with ABA in combination with PTCY, tacrolimus, and mycophenolate mofetil...Reduced-intensity conditioning regimens were used in the majority of patients in both cohorts (88.2% vs 93.4%, p=0.5), most commonly conditioning included busulfan-fludarabine or busulfan-cyclophosphamide-fludarabine. In the +56 cohort, 2 patients received clofarabine-melphalan, according to internal protocol, due to disease persistence prior to transplant.With a median follow-up of 15.7 months (range 7.4–31.1), estimated 1-year PFS and OS were 66% (IC95%= 0.5-0.7) and 72% (IC95%= 0.5-0.8)... Our experience suggests, compared with previous analysis ( P Fernandez-Caldas. EBMT 2024 ), that addition of ABA to PTCY-based prophylaxis, in peripheral blood stem cell setting, may reduce GVHD and allow early immunosuppression withdrawal without increasing GVHD rates, though sample size is limited."

Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation • CTLA4

Real-world comprehensive single-institution analysis of AML with TP53-mutation (ASH 2025) - "For younger/fit patients (pts), intensive induction therapy is often considered while hypomethylating agents (HMA's) with or without venetoclax remains the standard for older/unfit pts...Frontline treatment regimens were stratified by intensive induction therapy (IIT) including 7+3 with or without cladribine, CPX-351, or clofarabine, cytarabine, G-CSF (CLAG) with or without investigational therapies...AlloSCT was associated with improved OS outcomes, although a limited proportion of patients were able to proceed to alloSCT as consistent with previously published data. These findings underscore the urgent need to develop novel therapeutic strategies, prioritize clinical trial options, and optimize alloSCT selection and timing for patients with TP53m AML."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • TP53

Prospective study of patient-reported depression, and cognitive and functional impairment, and impact on survival and induction mortality in fit adults age ≥60 years receiving intensive chemotherapy (IC) for Acute Myeloid Leukemia (AML): Prospective geriatric assessment (GA) report from ECOG-ACRIN (EA) E2906 randomized study (ASH 2025) - "A patient-reported outcomes (PRO) assessment of Depression, Activities of Daily Living(ADL), Cognitive Function, Social Support (SS) domains, and comorbidity was performed at studyregistration to evaluate the prevalence of vulnerabilities and their impact on overall survival (OS) and 30-day induction mortality rates (IM) in this cohort selected for fitness to receive IC.MethodsE2906 study design and results have been presented previously [n=727, age ≥60 years, randomized 1:1 to'standard 7&3' & high dose cytarabine (Arm A) vs. single agent clofarabine (CLO, Arm B), as remissioninduction (Step 1) and consolidation (Step 2)]. This suggests thatfunctional and cognitive impairments are prevalent and can significantly impact outcome even in fit olderadults. Despite potential long-term OS advantages of IC previously observed in E2906, efforts tosystematically recognize those at higher risk based on GA PROs are needed to help identify patients whomay be more..."

Clinical • Acute Myelogenous Leukemia • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Geriatric Disorders • Hematological Malignancies • Leukemia • Mood Disorders • Psychiatry

Targeting ribonucleotide reductase to overcome FLT3 Inhibitor Resistance in acute myeloid leukemia (ASH 2025) - "Notably, several FDA-approved drugs, such as clofarabine and fludarabine, areknown RNR inhibitors. We propose repurposing these agents to overcome FLT3i resistance in AML.Together, these findings establish RNR as a promising therapeutic target to circumvent NRAS-mediatedFLT3i resistance in AML."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • FLT3 • NRAS

High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701) (ASH 2025) - P2 | "Based upon retrospectivedata showing low rates of relapse, we hypothesized that patients with negative pre-HCT MRD by next-generation-sequencing of IgH B-cell receptor rearrangements (NGS-MRD) could achieve 2-year EFSexceeding 75% with a non-TBI regimen, an outcome comparable to those receiving TBI-based regimens. The Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) conducted a phase IIprospective trial at 45 Centers in North America (ONC1701 EndRAD: NCT03509961) between 2018 and2025 to evaluate outcomes of myeloablative non-TBI conditioning regimens for allogeneic HCT in B-ALLpatients at lower risk for relapse defined by absence of NGS-MRD (Clonoseq) of B-cell receptorrearrangements (BCR) just prior to HCT...Mismatched related/haploidentical grafts received post-transplant cyclophosphamide orTCRαβ/CD19 depletion according to institutional preference...Of patientsenrolled, 33% were White/Non-Hispanic, 37% Hispanic, 12% Black or African American, and..."

Biomarker • Clinical • IO biomarker • Minimal residual disease • Next-generation sequencing • Residual disease • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Transplantation

Advances in the Diagnosis and Management of Pediatric Langerhans Cell Histiocytosis and Rosai-Dorfman Disease: Therapies, Biomarkers, and Response Assessment (ASH 2025) - "Eckstein will discuss frontline and salvage treatment strategies, including the use of vinblastine, cytarabine, clofarabine, and targeted agents such as BRAF and MEK inhibitors, as well as practical approaches to monitoring disease response and managing CNS involvement. Real-world challenges in treating refractory or relapsed disease will be addressed, alongside strategies for integrating molecular diagnostics and emerging therapies into routine practice. Attendees will gain actionable insights into optimizing outcomes for children and adults with these rare histiocytic disorders."

Biomarker • Clinical • Langerhans Cell Histiocytosis • Pediatrics • Rare Diseases

Down the Rabbit Hole: An Update on Histiocytic Disorders (ASH 2025) - "She will outline current guidelines for risk stratification, discuss frontline and salvage therapy options — including vinblastine, cytarabine, clofarabine, and targeted therapies — and address the role of MAPK and other molecular drivers in therapeutic decision-making. Drawing from real-world cases, he will highlight diagnostic tools, prognostic scoring systems, and the evolving landscape of personalized treatment. Emphasis will be placed on how hematologists can optimize their approach to HLH in high-risk inpatient settings and in collaboration with multidisciplinary teams.Attendees will gain practical, case-driven insights into the evolving classification, molecular landscape, and treatment strategies for histiocytic neoplasms across diverse clinical contexts."

Preclinical • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Langerhans Cell Histiocytosis • Rare Diseases • Septic Shock

Bisantrene in Combination with Fludarabine and Clofarabine As Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)- an Open-Label, Phase II, Study (ASH 2023) - P2 | "Background: Bisantrene (Bis), is a topoisomerase-II inhibitor with anthracycline-like activity, lower cardiotoxicity, and activity in patients (pts) with relapsed (rel)/primary refractory (PR) acute myeloid leukemia (AML) (Am J Hematol, 2021). In this Phase II study in a very advanced group of relapsed refractory AML pts resistant to multiple previous lines of chemotherapy including transplantation and with a median of 50% blasts at study initiation, Bis/Clo/Flu combination therapy was found to be safe and well tolerated without cardiac toxicity or tumor lysis syndrome. The maximum length of Bis/Clo/Flu administration was 4 days due to rapidly reversible liver toxicity, and transaminitis. As expected in this highly pretreated population, the infection rates were high."

Clinical • Combination therapy • P2 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cardiovascular • Febrile Neutropenia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Thrombosis • Transplantation • KMT2A

Outcomes and Toxicities after Allogeneic Hematopoietic Cell Transplant for Remission Consolidation or Relapse Therapy after CD19 Chimeric Antigen Receptor T Cell Therapy in Children and Young Adults with Acute Lymphoblastic Leukemia (ASH 2023) - "In the relapse cohort, salvage therapies that successfully induced HCT-acceptable remissions (MRD <0.1%) included inotuzumab (n=11, 50%), cytotoxic chemotherapy (n=5, 23%), blinatumomab (n=2, 9%), CART22 (n=2, 9%), CART19 reinfusion (n=1, 5%), or pembrolizumab (n=1, 5%)...All patients received myeloablative conditioning, either total body irradiation-based (n=39) or clofarabine-based (n=2), and 59% received a T cell depleted graft... In children receiving their first HCT for post-CART19 remission consolidation, DFS and OS were exceptionally good, without any observed TRM and with comparable rates of GVHD and other major complications to general pediatric HCT populations. For children who were able to undergo HCT following a post-CART19 relapse, of which 77% were in CR3 or later, DFS and OS were also favorable. The majority became long term survivors and all events occurred within 1 year after HCT."

CAR T-Cell Therapy • Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Leukemia • Oncology • Pediatrics • Pneumonia • Respiratory Diseases • Transplantation

A Bibliometric Analysis of Drug Resistance in Pediatric Acute Lymphoblastic Leukemia. (PubMed, Adv Biomed Res) - "Based on the thematic map, the keywords of the motor themes were clofarabine, nelarabine, daunorubicin, vincristine, and microRNA, illustrating the need for further investigation of their clinical applications and the underlying mechanisms of resistance to these agents. Medical researchers have been attracted to different aspects of drug resistance in pediatric ALL. This bibliometric analysis reflects the current state of research on drug resistance in pediatric ALL and draws attention to critical concerns that require further investigation."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pediatrics

Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - P2 | N=72 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Oct 2025 ➔ Sep 2026

Trial completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • T Acute Lymphoblastic Leukemia • Transplantation • HLA-B • HLA-C

TP53-Mutated Acute Myeloid Leukemia Patients Treated with Intensive Therapies Have Superior Outcomes: A Single Institution, Retrospective Study (ASH 2023) - "Intensive treatment regimens included infusional cytarabine with either daunorubicin or idarubicin (7+3), liposomal cytarabine and daunorubicin (CPX-351), and mitoxantrone, etoposide and cytarabine (MEC). Nonintensive regimens included hypomethylating agents (decitabine or azacitidine) with or without venetoclax and clofarabine with low-dose subcutaneous cytarabine... In our cohort, TP53 mutant AML patients treated with intensive chemotherapy and transplant have superior outcomes to those who do not. Since this was a retrospective study, we cannot rule out the possibility that these results are confounded by providers favoring more intensive therapies for fitter patients. However, these data imply that TP53 mutant patients may benefit from more intensive therapy and suggests that future work to define optimal therapy regimens in this patient population may incorporate intensive strategies."

Retrospective data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Sarcoma • Solid Tumor • ASXL1 • KRAS • NRAS • TP53

Acute Myeloid Leukemia with Inv(3) or t(3; 3): A Clinical and Cytogenetic Characterization of 40 Patients (ASH 2023) - "Salvage therapies for patients included re-induction with 7+3, FLAG-Ida, mitoxantrone-containing regimens, clofarabine-based protocols, or combination of hypomethylating agents with venetoclax. In summary, de novo AML inv(3)/t(3; 3) is a rare and aggressive subtype of AML conferring extremely poor prognosis. There appears to be an increase of incidence in females affecting a slightly younger demographic. Consistent with previous studies, the presence of chr 7 abnormalities was associated with even worse outcomes, which interestingly also drive EVI1 overexpression."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation • GATA2 • MECOM

Sequential Conditioning Regimen with Thiotepa, Clofarabine and Busulfan (TEC/CloB2A2) and Post-Transplant Cyclophosphamide in Adults with Refractory AML: A Retrospective Monocentric Study (ASH 2023) - "Recently, a combination of thiotepa, etoposide, cyclophosphamide (TEC) followed by fludarabine/busulfan/ATG (FB2A2) using any type of donor for refractory hematologic malignancies have shown some promising results (Dulery, 2018)...The TEC/CloB2A2 regimen consisted of Thiotepa 5 mg/kg at day(d)-13, Cyclophosphamide 400 mg/m²/d from d-12 to d-9 and Etoposide phosphate 100 mg/m²/d from d-12 to d-9, followed after 3 days of rest, by Clofarabine 30 mg/m²/d from d-5 to d-1, Busulfan 3,2 mg/kg/d d-5 and d-4 and Thymoglobuline 2,5 mg/kg/d d-3 and d-2. GVHD prophylaxis consisted of high-dose of post-transplant Cyclophosphamide (PTCY) 50 mg/kg/d at d+3 and d+5 in combination with mycophenolate mofetyl and cyclosporine starting at d+6...Six out of 8 CR/CRp patients received maintenance treatment after transplant to prevent relapse using 5'azacytidine alone in 1, 5 azacytidine+ donor lymphocyte infusion (DLI) in 2, DLI alone in 1... The sequential TEC/CloB2A2..."

Post-transplantation • Retrospective data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Acute Respiratory Distress Syndrome • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Septic Shock • Transplantation

Clofarabine and High-Dose Melphalan Reduced Intensity Conditioning Regimen with Methotrexate-Based GvHD Prophylaxis (ASH 2023) - "Fludarabine-containing regimens make up the cornerstone of RIC regimens, however, during the nation-wide fludarabine shortage in 2022, many institutions used fludarabine-free RIC regimens out of necessity though data was extremely limited. CloMel demonstrated similar efficacy outcomes at 6 months and represents a feasible alternative to FluMel as a RIC regimen. However, given the notable occurrence of renal failure and early death in the CloMel arm, careful consideration and particular caution in administering to patients with a prior history of renal disease is recommended."

Acute Kidney Injury • Chronic Graft versus Host Disease • Chronic Kidney Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Nephrology • Non-Hodgkin’s Lymphoma • Oncology • Septic Shock

Responses to Combination Chemotherapy with MAPK Pathway Inhibition in Relapsed and Refractory LCH (ASH 2023) - "Almost all Clofarabine was administered outpatient (typical starting dose 25 mg/m2/day x 5 days)...Combining therapy was well-tolerated and associated with clinical and molecular improvement in most patients with highly refractory systemic LCH and LCH-ND. Further prospective multi-center trials are required to optimize this approach, determine potential for combination therapy to achieve cure, and compare risks and benefits to chemotherapy or MAPK inhibitor monotherapy."

Ataxia • CNS Disorders • Dermatology • Hematological Disorders • Langerhans Cell Histiocytosis • Movement Disorders • Musculoskeletal Pain • BCL2L1

Retrospective Analysis of Clofarabine Salvage Therapy in Refractory Multifocal Langerhans Cell Histiocytosis (LCH) (ASH 2023) - "Clofarabine monotherapy has activity against LCH in heavily pretreated patients, the majority of whom achieved durable remission. Prospective multi-center trials are warranted to determine optimal dosing as well as long-term efficacy, late toxicities, relative cost and patient reported outcomes of clofarabine compared to alternative salvage therapy strategies (e.g. MAPK inhibitors) in patients with relapsed/refractory LCH."

Retrospective data • CNS Disorders • Hematological Disorders • Infectious Disease • Langerhans Cell Histiocytosis

Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR) (ASH 2024) - "Five had reticulohistiocytoma : 2 had observation (complete response - CR), and 2 oral chemotherapy (1 PR; 1 resistant had PR after everolimus). Sixteen were systemic : 3 (19%) had vinblastine/steroids - LCH-III (CR), 1 surgery (CR), and 2 observation (1 CR; 1 stable disease - SD); 7 (44%) had relapsed/refractory (R/R) disease : 2 had cladribine or surgery (PR), and 5 others were refractory to cladribine or clofarabine (1 PR after MEK-I)...Five intraocular : 3 had surgery (CR/PR), 2 resistant to oral chemotherapy had MEK-I (1 CR; 1 SD after intrarterial melphalan)...BRAF/MEK-I induced more responses (81% overall response rate - ORR) than conventional therapies (interferon-α, chemotherapy, anakinra, radiation; 55% ORR) as first-line or salvage therapy...Twenty-seven were systemic : 11 (41%) had oral chemotherapy (73% ORR), 3 (27%) R/R had cladribine (all PR); 2 had surgery (75% ORR), 5 observation (40% ORR); 2 had indomethacin or radiotherapy (SD); 5 (19%) R/R received..."

IO biomarker • Hematological Malignancies • Juvenile Myelomonocytic Leukemia • Musculoskeletal Diseases • Oncology • Rare Diseases • ALK • BRAF • KRAS • MAP2K1

Comparison of Two Reduced Intensity Conditioning Regimens (Baltimore with Clofarabine vs Thiotepa-Busulfan-Fludarabine) in Adults Receiving Peripheral Blood Stem Cell Haploidentical Transplantation for Myeloid Malignancies: A Retrospective Study of the SFGM-TC (ASH 2023) - "CloB consisted of clofarabine 30 mg/m²/day (d) 5 d, cyclophosphamide (Cy) 14.5mg/kg/d 2 d, and 2-Gy TBI on d-2...Graft-versus-host disease (GVHD) prophylaxis consisted of post-transplant Cy (2 doses of 50mg/kg), followed by cyclosporine A and mycophenolate mofetil starting on d+5... In this retrospective study, a TBF RIC regimen used for PBSC haploT in adults with myeloid malignancies appeared substantially more toxic than a CloB RIC regimen. However, its enhanced anti-leukemic effect suggests that it should be offered to younger patients with no comorbidities or to those with high-risk disease. Conversely, CloB should be proposed for older or frail patients."

Retrospective data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

Older Adults with Acute Myeloid Leukemia (AML) Experience Improvement in Health-Related Quality of Life (HRQoL) Scores with Intensive Therapy: Prospective Study from ECOG-ACRIN (EA) E2906 Phase 3 Trial (ASH 2023) - "In the recent EA E2906 phase 3 study of '7&3' (daunorubicin & cytarabine) vs. clofarabine (CLO), a putative lower intensity therapy, we incorporated a prospective patient-reported outcomes (PRO) assessment of HRQoL and fatigue to understand treatment impact from the patients' (pts) perspective. Patient-reported HRQoL & Fatigue was not predictive of completion of protocol therapy. These results serve as a benchmark for expectations with IC in older adults."

Clinical • HEOR • P3 data • Acute Myelogenous Leukemia • Fatigue • Hematological Malignancies • Leukemia • Oncology

Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes (ASH 2023) - P3 | "Patients received high-dose cytarabine, daunorubicin, and etoposide (HDAC), low-dose cytarabine, daunorubicin, and etoposide (LDAC), or clofarabine and cytarabine (Clo/AraC) as initial therapy. By contrast, black patients with high ACS10 scores did not appear to benefit from HDAC or Clo/Ara-C induction. Our results suggest that pharmacogenomics differences between black and white patients should be considered when tailoring induction regimens to improve outcomes of black patients and bridge the racial disparity gap in AML treatment."

Biomarker • Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

Long-Term Survival of Patients with Relapsed/Refractory Acute Leukemia Receiving Clofarabine/Cyclophosphamide Prior to Hematopoietic Stem Cell Transplantation (ASH 2024) - "For prophylaxis of graft versus host disease (GVHD) cyclosporine with methotrexate or mycophenolate mofetil was used. This was also confirmed in multivariate analysis were acute aGVHD (OS, p=0.016; RFS, p=0.016) and cGVHD (OS, p=0.023; RFS, p=0.036) were the only independent prognostic variables whereas age, type of disease, duration of therapy with ClofCy and type of refractory disease (R versus RR) were not found to be independent prognostic variables.Conclusion : ClofCy is a new promising debulking strategy for patients with R/RR acute leukemias prior to HSCT although the relatively low number of patients and the retrospective character of our study were limiting factors. According to our results, ClofCy should be introduced early in such cases and cGVHD seems to be a good prognostic factor regarding OS and RFS."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cerebral Hemorrhage • Chronic Graft versus Host Disease • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mast Cell Leukemia • Oncology • Transplantation

Outcomes of Allogeneic Transplantation with Clofarabine and Post-Transplant Cyclophosphamide-Based Conditioning in Patients with Very High-Risk Acute Myeloid Leukemia (ASH 2024) - "The intermediate-intensity regimen (TCI 2.5) consisted of Clo 30 mg/m² (for 5 days) plus Melphalan 140 mg/m² on day -2, while the high-intensity regimen (TCI 4) consisted of Clo 40 mg/m² (for 5 days) plus Busulfan 3.2 mg/kg/day (for 4 days). All patients received PT-CY on days +3 and +4, followed by a calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF) from day +5...The relapse incidence at three years was 26%, with no differences in subgroup analysis for higher risk (active disease at transplant and TP53 mutation). Conclusions : In our experience, the incorporation of Clo to the conditioning regime in patients with very high relapse-risk AML, including visible disease at transplantation, using peripheral blood and post-transplant cyclophosphamide GVHD prophylaxis with both matched and haploidentical donors, offers favorable outcomes for this population, which has historically presented adverse results."

Clinical • Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Dermatology • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hepatology • Immunology • Leukemia • Mucositis • Oncology • Transplantation • TP53

Treosulfan Vs Busulfan As Part of Clofarabine Based Reduced Intensity Conditioning Regimen before Allotransplant for Myeloid Malignancies (ASH 2024) - "Recently, treosulfan replacing busulfan as part of a fludarabine/busulfan RIC regimen was shown to provide better survival thanks to a lower non relapse mortality in older or comorbid allotransplanted patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (Beelen, Lancet Haematology 2019)...The former consisted of clofarabine 30 mg/m2/day 5 days, busulfan 3.2 mg/kg/day 2 days and 2.5 mg/kg/day of rabbit anti-thymocyte globulin 1 or 2 days (CLOB2A1/A2)...Beside ATG, graft-versus-host disease (GVHD) prophylaxis consisted for both groups of ciclosporine and mycophenolate mofetil (MMF)...However, CloT3 is associated with significant lower RI but higher incidence of GVDH-related deaths in AML patients. These results have to be confirmed on larger prospective studies using maybe reinforced GVHD prophylaxis."

Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation • CD34